Zydus US004
Welcome,         Profile    Billing    Logout  
 0 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Myers, Jessica Jessica
SARO.20.002, NCT05011305: Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis with Fibrosis

Active, not recruiting
2
180
US, RoW
Saroglitazar Magnesium 2 mg, Investigational Product, Saroglitazar Magnesium 4 mg, Placebo, Comparator Agent
Zydus Therapeutics Inc.
Nonalcoholic Steatohepatitis, Fibrosis
07/25
07/25
ECLIPSE, NCT04136002: Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

Active, not recruiting
N/A
44467
US
Guardant Health, Inc., Premier Research Group plc
Colorectal Cancer
03/24
12/25
Pritchard, Natalie
NCT04638647 / 2020-004284-98: Secukinumab Open Label Roll-over Extension Protocol

Recruiting
4
715
Europe, US, RoW
Secukinumab s.c. injection
Novartis Pharmaceuticals
Autoimmunity, Inflammation
12/27
02/28
NCT05603754: A Study Utilizing Patient-Reported Outcomes to Evaluate the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (STRIDES)

Completed
3
496
US
Lorecivivint, SM04690, Placebo, Vehicle
Biosplice Therapeutics, Inc., NBCD A/S
Knee Osteoarthritis
02/24
02/24
SARO.20.002, NCT05011305: Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis with Fibrosis

Active, not recruiting
2
180
US, RoW
Saroglitazar Magnesium 2 mg, Investigational Product, Saroglitazar Magnesium 4 mg, Placebo, Comparator Agent
Zydus Therapeutics Inc.
Nonalcoholic Steatohepatitis, Fibrosis
07/25
07/25

Download Options